News

Genentech, a wholly-owned member of the Roche Group and Biogen Idec have received a complete response from the FDA for a supplemental Biologics License Application (sBLA) for Rituxan

Roche has presented the results of a two-year data from the Lithe study at the American College of Rheumatology (ACR). Reportedly, with long-term use, patients with rheumatoid arthritis

Data presented at the 73rd annual scientific meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to

UCB has reported that Cimzia (certolizumab pegol), together with methotrexate (MTX), has showed sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early

The FDA has approved AstraZeneca’s Crestor (rosuvastatin calcium) for use in children between 10-17 ages with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol.

Access Pharmaceuticals (Access ) has provided an update on it’s European launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment

The FDA has approved GlaxoSmithKline’s (GSK) Cervarix [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic

Generex Biotechnology (Generex) together with Continental Pharma Laboratories, the company’s importation, marketing, distribution, and sales agent in Algeria, has reported the launch of commercial sales of Generex Oral-lyn

Pharming Group has reported net loss E23.1m for the third quarter which ended on September 30, 2009. Basic and diluted earnings per share decreased to E0.22 compared to